Addex Therapeutics (ADXN) Competitors $8.00 +0.46 (+6.11%) As of 08/14/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADXN vs. RANI, KPTI, OVID, ENLV, XLO, MRSN, SNYR, CLSD, ALXO, and AKTXShould you be buying Addex Therapeutics stock or one of its competitors? The main competitors of Addex Therapeutics include Rani Therapeutics (RANI), Karyopharm Therapeutics (KPTI), Ovid Therapeutics (OVID), Enlivex Therapeutics (ENLV), Xilio Therapeutics (XLO), Mersana Therapeutics (MRSN), Synergy CHC (SNYR), Clearside Biomedical (CLSD), ALX Oncology (ALXO), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical products" industry. Addex Therapeutics vs. Its Competitors Rani Therapeutics Karyopharm Therapeutics Ovid Therapeutics Enlivex Therapeutics Xilio Therapeutics Mersana Therapeutics Synergy CHC Clearside Biomedical ALX Oncology Akari Therapeutics Rani Therapeutics (NASDAQ:RANI) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership. Does the media prefer RANI or ADXN? In the previous week, Rani Therapeutics had 4 more articles in the media than Addex Therapeutics. MarketBeat recorded 5 mentions for Rani Therapeutics and 1 mentions for Addex Therapeutics. Addex Therapeutics' average media sentiment score of 1.87 beat Rani Therapeutics' score of 0.94 indicating that Addex Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Rani Therapeutics Positive Addex Therapeutics Very Positive Which has more volatility & risk, RANI or ADXN? Rani Therapeutics has a beta of -0.02, meaning that its share price is 102% less volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500. Is RANI or ADXN more profitable? Addex Therapeutics has a net margin of 3,584.49% compared to Rani Therapeutics' net margin of 0.00%. Addex Therapeutics' return on equity of -54.27% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rani TherapeuticsN/A -2,272.39% -97.97% Addex Therapeutics 3,584.49%-54.27%-49.15% Do insiders & institutionals have more ownership in RANI or ADXN? 30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 45.1% of Rani Therapeutics shares are held by insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts prefer RANI or ADXN? Rani Therapeutics presently has a consensus price target of $7.33, indicating a potential upside of 1,217.05%. Addex Therapeutics has a consensus price target of $30.00, indicating a potential upside of 273.37%. Given Rani Therapeutics' higher possible upside, equities analysts clearly believe Rani Therapeutics is more favorable than Addex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rani Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Addex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings and valuation, RANI or ADXN? Addex Therapeutics has lower revenue, but higher earnings than Rani Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRani Therapeutics$1.03M34.17-$30.02M-$0.91-0.61Addex Therapeutics$460K18.52$8.02M-$0.34-23.63 SummaryRani Therapeutics beats Addex Therapeutics on 8 of the 15 factors compared between the two stocks. Get Addex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXN vs. The Competition Export to ExcelMetricAddex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.99M$2.48B$5.61B$9.84BDividend YieldN/A1.76%4.61%4.07%P/E Ratio-23.6322.0530.2825.74Price / Sales18.52742.42460.47115.79Price / CashN/A184.4138.2159.48Price / Book0.774.838.856.15Net Income$8.02M$31.61M$3.25B$265.06M7 Day Performance2.04%4.55%3.72%2.60%1 Month Performance-11.01%5.69%5.86%2.83%1 Year Performance3.01%12.71%30.34%25.58% Addex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXNAddex Therapeutics2.7389 of 5 stars$8.04+6.6%$30.00+273.4%+3.0%$7.99M$460K-23.6330Positive NewsGap UpRANIRani Therapeutics3.4968 of 5 stars$0.56+2.2%$7.33+1,209.5%-79.1%$35.40M$1.20M-0.57110Short Interest ↓KPTIKaryopharm Therapeutics3.6495 of 5 stars$4.09+1.7%$37.40+814.4%-61.6%$35.34M$145.24M-0.31380Earnings ReportAnalyst ForecastAnalyst RevisionOVIDOvid Therapeutics4.4382 of 5 stars$0.50-0.3%$3.13+531.3%-16.8%$35.20M$570K-1.4160Trending NewsEarnings ReportShort Interest ↑Gap DownENLVEnlivex Therapeutics3.3568 of 5 stars$1.48-0.3%$10.00+577.5%+42.4%$35.00MN/A-2.2470News CoverageShort Interest ↓XLOXilio Therapeutics2.8464 of 5 stars$0.66+1.1%$4.00+502.4%-14.8%$34.38M$6.34M-0.7970News CoverageEarnings ReportMRSNMersana Therapeutics4.0981 of 5 stars$6.77-1.4%$130.00+1,821.7%-75.9%$33.76M$40.50M-0.46150Trending NewsEarnings ReportAnalyst ForecastShort Interest ↓SNYRSynergy CHC4.0858 of 5 stars$3.58+2.0%$10.00+179.3%N/A$32.90M$34.83M0.0040News CoverageEarnings ReportCLSDClearside Biomedical2.8119 of 5 stars$0.42+1.2%$4.20+900.0%-56.0%$32.72M$1.66M-1.0330Earnings ReportShort Interest ↑Gap UpALXOALX Oncology2.9092 of 5 stars$0.61+3.8%$3.30+441.9%-74.6%$32.41MN/A-0.2540Earnings ReportAKTXAkari Therapeutics3.0984 of 5 stars$1.00-3.4%$5.00+402.5%-69.5%$32.02MN/A0.009Upcoming Earnings Related Companies and Tools Related Companies Rani Therapeutics Alternatives Karyopharm Therapeutics Alternatives Ovid Therapeutics Alternatives Enlivex Therapeutics Alternatives Xilio Therapeutics Alternatives Mersana Therapeutics Alternatives Synergy CHC Alternatives Clearside Biomedical Alternatives ALX Oncology Alternatives Akari Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXN) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access